Pursuant to Regulation 30 read with Schedule III of the SEBI Listing Obligations and Disclosure Requirements), Regulations, 2015, NGL Fine-Chem has informed that, Crisil Ratings vide their letter dated March 12, 2026 has revised its outlook on the long-term bank loan facilities of the Company to ‘Stable’ from ‘Negative’ while reaffirming the rating at ‘Crisil BBB+’. The Short term rating has been reaffirmed at 'Crisil A2'.
The above information is a part of company’s filings submitted to BSE.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1654.70 |
| Dr. Reddys Lab | 1232.00 |
| Cipla | 1229.60 |
| Zydus Lifesciences | 915.45 |
| Lupin | 2332.70 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: